Business
BioMarin pays USD 275m upfront for early-stage oral HPP bet ALE1
BioMarin Pharmaceutical (Nasdaq: BMRN) has agreed to acquire Alesta Therapeutics for USD 275 million upfront plus up to USD 215 million in development and...
SciSparc funds NeuroThera Labs spinoff with CAD 5.4m financing round
Vancouver-based NeuroThera Labs Inc. (TSXV: NTLX) has completed a non-brokered private placement in two tranches, raising aggregate gross proceeds of CAD...
Abcuro raises USD 66m to retest ulviprubart after Phase II/III IBM miss
Newton, Massachusetts-based Abcuro, Inc. has closed a USD 66 million Series D financing to fund a new potentially registrational study of ulviprubart, its...
LEO Pharma picks up dersimelagon for USD 435m to challenge Scenesse in rare photodermatoses
Denmark-based LEO Pharma has agreed to acquire worldwide rights to dersimelagon, an oral melanocortin 1 receptor (MC1R) agonist for two ultra-rare...
Ingenia Therapeutics lists on KOSDAQ to fund vascular antibody pipeline
Watertown, Massachusetts-based Ingenia Therapeutics, a clinical-stage biotech whose lead ophthalmology antibody is being developed by Merck, began trading...
Lilly taps OmniAb for ion channel discovery in deal worth up to USD 370m
Emeryville, California-based OmniAb (Nasdaq: OABI) has signed a global collaboration and license agreement with Eli Lilly (NYSE: LLY) for a new ion channel...
Slate Medicines goes public via Fulcrum merger to challenge PACAP migraine field
Raleigh, North Carolina-based Slate Medicines, Inc. will gain a Nasdaq listing through an all-stock reverse merger with Cambridge, Massachusetts-based...
J&J hands C-CAR039 back to AbelZeta amid pivot toward in vivo CAR-T
AbelZeta Pharma reclaimed full global rights to its anti-CD19/CD20 bispecific CAR-T cell therapy prizloncabtagene autoleucel (C-CAR039) from Janssen Biotech...
BioCytics and LIDE Biotech partner to validate immune cell therapies in patient-derived tumor models
Huntersville, North Carolina-based BioCytics, Inc. and Shanghai-based preclinical oncology contract research organization LIDE Biotech have announced a...
Leal Therapeutics raises USD 30m to advance glutaminase inhibitor in schizophrenia
Worcester, Massachusetts-based Leal Therapeutics, Inc. has closed a USD 30 million Series A extension — the second close of its Series A — alongside the...
Aizen lands multi-program oral peptide deal worth up to USD 100m per target
San Diego-based Aizen Therapeutics has entered a multi-program collaboration with an undisclosed San Diego-based public biotech to apply its DaX artificial...
Silence Therapeutics completes private fund raise at USD 201.3m for divesiran trial
UK-based Silence Therapeutics plc (Nasdaq: SLN) announced the closing of an upsized public offering of American Depositary Shares (ADSs), raising...
Sandoz expands Henlius partnership to cover up to 10 biosimilars for USD 322m
Shanghai Henlius Biotech (HKEX: 2696) and Sandoz (SIX: SDZ; OTCQX: SDZNY) have expanded their biosimilars collaboration into a platform-level deal covering...
Redx takes control of Skye in Nasdaq combination backed by USD 125m financing
San Diego-based Skye Bioscience, Inc. (Nasdaq: SKYE) announced a definitive agreement to acquire UK-based Redx Pharma Limited alongside USD 125 million in...
Atrium collects second USD 15m milestone from BMS as cardiovascular RNA programs advance
San Diego-based Atrium Therapeutics (Nasdaq: RNA) has earned a second USD 15 million development milestone from Bristol Myers Squibb (NYSE: BMY) under their...
The AllSci Brief
Free, systematic R&D and deal news. Daily.